Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Status and phase: Enrolling; Phase 2

Conditions: Solid Tumor, Adult; Hepatocellular Carcinoma

Treatments: Drug: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

Study type: Interventional

Funder types: Other

Identifiers

NCT04803318

ZZ3TKI-011

Details and patient eligibility

About

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Full description

The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent/Refractory advanced solid tumors
• Age between 18 and 85 years
• Expected life expectancy is greater than three months

Exclusion criteria

• Benign tumor
• Life expectancy is less than three months
• Serious medical commodities
• others

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Combination treatment of 3 inhibitors

Experimental group

Description:

Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.

Treatment:

Drug: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib